Katja Conrath

Company: MRM Health

Job title: Chief Scientific Officer

Seminars:

Mechanistic Insights from a Phase 2a Study with MH002, an Optimised Consortia Therapeutic Evaluated in Ulcerative Colitis Patients 12:45 pm

Outlining MH002, a 6-strain consortia therapeutic designed, optimised and manufactured through MRM Health’s CORAL® technology, the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis Receiving first-time insight on the translation of the mechanism of action of MH002 in activity in Ulcerative Colitis patients – results from a placebo-controlled randomized Phase 2a…Read more

day: Day 1 Track A AM